HomeCompareBMXXY vs KMB

BMXXY vs KMB: Dividend Comparison 2026

BMXXY yields 0.79% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMXXY wins by $2.12M in total portfolio value· pulled ahead in Year 5
10 years
BMXXY
BMXXY
● Live price
0.79%
Share price
$12.44
Annual div
$0.10
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.16M
Annual income
$1,739,853.91
Full BMXXY calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — BMXXY vs KMB

📍 BMXXY pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMXXYKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMXXY + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMXXY pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMXXY
Annual income on $10K today (after 15% tax)
$67.12/yr
After 10yr DRIP, annual income (after tax)
$1,478,875.82/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, BMXXY beats the other by $1,474,446.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMXXY + KMB for your $10,000?

BMXXY: 50%KMB: 50%
100% KMB50/50100% BMXXY
Portfolio after 10yr
$1.10M
Annual income
$872,532.61/yr
Blended yield
79.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

BMXXY
No analyst data
Altman Z
7.5
Piotroski
7/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMXXY buys
0
KMB buys
0
No recent congressional trades found for BMXXY or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMXXYKMB
Forward yield0.79%5.25%
Annual dividend / share$0.10$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%17%
Portfolio after 10y$2.16M$45.9K
Annual income after 10y$1,739,853.91$5,211.33
Total dividends collected$2.11M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: BMXXY vs KMB ($10,000, DRIP)

YearBMXXY PortfolioBMXXY Income/yrKMB PortfolioKMB Income/yrGap
1$10,858$157.93$11,314$613.68$456.00KMB
2$11,938$320.51$12,865$759.19$927.00KMB
3$13,433$658.71$14,709$943.96$1.3KKMB
4$15,759$1,385.36$16,919$1,180.17$1.2KKMB
5← crossover$19,899$3,037.77$19,588$1,484.33+$311.00BMXXY
6$28,462$7,170.10$22,838$1,879.06+$5.6KBMXXY
7$49,624$19,169.19$26,832$2,395.60+$22.8KBMXXY
8$115,567$62,469.69$31,788$3,077.63+$83.8KBMXXY
9$395,588$271,931.01$38,000$3,986.82+$357.6KBMXXY
10$2,163,133$1,739,853.91$45,872$5,211.33+$2.12MBMXXY

BMXXY vs KMB: Complete Analysis 2026

BMXXYStock

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Full BMXXY Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this BMXXY vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMXXY vs SCHDBMXXY vs JEPIBMXXY vs OBMXXY vs KOBMXXY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.